The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Open accessAbstract
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [39]
In the citing paper
“First-line nivolumab + ipilimumab treatment also produced longer OS than chemotherapy in patients with advanced NSCLC10.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“First-line nivolumab + ipilimumab resulted in a longer duration of OS than chemotherapy in patients with metastatic NSCLC, irrespective of the PD-L1 expression10,28.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“most notably the combination of pembrolizumab and axitinib (an inhibitor of vascular growth factor inhibitor) in renal cell carcinoma.15”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [15]
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
In the citing paper
“Moreover, the data of CheckMate-214, CheckMate-227, and CheckMate-743 indicated the superior efficacy of ipilimumab plus nivolumab over the standard targeted therapy or chemotherapy [135–137].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,003
Carroll, R., Bortolini, M., Calleja, A., Munro, R. E. J., Kong, S., Daumont, M., Penrod, J. R., Lakhdari, K., Lacoin, L., & Cheung, W. Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09342-5 · Cited by 28
Ding, Z., Meng, G.-X., Xue, J.-S., Yan, L., Liu, H., Yan, Y., Chen, Z., Hong, J., Wang, D., Dong, Z., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04133-8 · Cited by 28
Zhang, Q., Gong, X., Sun, L., Miao, L., & Zhou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.791496 · Cited by 29
Lin, E. P.-Y., Hsu, C., Berry, L. D., Bunn, P. A., & Shyr, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.27211 · Cited by 29
Shiraishi, Y., Tokito, T., Toyozawa, R., Inagaki, C., Nokihara, H., Kawashima, Y., Ohe, Y., & Okamoto, I. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.010 · Cited by 28
Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review
Wu, K. Y., Yakobi, Y., Gueorguieva, D. D., & Mazerolle, É. (2024) · Biomedicines · doi:10.3390/biomedicines12112547 · Cited by 28
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Martineau, R., Susini, S., & Marabelle, A. (2024) · Immunological Reviews · doi:10.1111/imr.13427 · Cited by 27
Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer
Liebler, D. C., Holzer, T. R., Haragan, A., Morrison, R. D., Reising, L. O., Ackermann, B. L., Fill, J. A., Schade, A. E., & Gruver, A. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-66902-0 · Cited by 28
Yamamoto, A., Yano, Y., Ueda, Y., Yasutomi, E., Hatazawa, Y., Hayashi, H., Yoshida, R., Asaji, N., Shiomi, Y., Tobimatsu, K., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03448-8 · Cited by 28
Sarfaty, M., Whiting, K. A., Teo, M. Y., Lee, C., Peters, V., Durocher, J., Regazzi, A. M., McCoy, A. S., Hettich, G., Jungbluth, A. A., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3699 · Cited by 27
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Passiglia, F., Reale, M. L., Cetoretta, V., & Novello, S. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s253581 · Cited by 27
Vasiliadou, I., Breik, O., Baker, H., Leslie, I., Sim, V., Hegarty, G., Michaelidou, A., Nathan, K., Hartley, A. G. J., Good, J. S., et al. (2021) · Cancers · doi:10.3390/cancers13061413 · Cited by 27
Morita, M., Okuyama, M., Akutsu, T., Ohdaira, H., Suzuki, Y., & Urashima, M. (2021) · Nutrients · doi:10.3390/nu13061987 · Cited by 27
Bjursten, S., Pandita, A., Zhao, Z., Frojd, C. A., Ny, L., Jensen, C., Ullerstam, T., Jespersen, H., Borén, J., Levin, M. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002732 · Cited by 27
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
Wang, C., Li, J., Zhang, Q., Wu, J., Xiao, Y., Song, L., Gong, H., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08662-2 · Cited by 27
Gu, J., Shi, L., Jiang, X., Wen, J., Zheng, X., Hu, C., & Zhang, W. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03140-5 · Cited by 27
Adverse events induced by nivolumab and ipilimumab combination regimens
Somekawa, K., Horita, N., Kaneko, A., Tagami, Y., Fukuda, N., Matsumoto, H., Namkoong, H., Fujiwara, Y., Minegishi, K., Fukumoto, T., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211058393 · Cited by 29
Felip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P. L., Trigo, J. M., Calvo, A., Kowalski, D. M., Cortinovis, D. L., Plummer, R., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04414-6 · Cited by 25
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee, J. Y., Kannan, B., Lim, B. Y., Li, Z., Lim, A. H., Loh, J. W., Ko, T. K., Ng, C. C. Y., & Chan, J. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147839 · Cited by 29
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 28
Kim, S., Kim, Y., Lee, S., Kim, Y., Jeon, B., Kim, H., & Park, H. (2022) · Cancers · doi:10.3390/cancers14174083 · Cited by 27
Self-citationTobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Corke, L., Li, J. J. N., Leighl, N. B., & Eng, L. (2022) · Current Oncology · doi:10.3390/curroncol29090492 · Cited by 27
Shao, T., Zhao, M., Liang, L., & Tang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948597 · Cited by 29
Lu, Y., Zhang, X., Ning, J., & Zhang, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2169531 · Cited by 28
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy
Wang, L., Jia, Q., Chu, Q., & Zhu, B. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2022.11.001 · Cited by 30
Huang, Y., Yang, Y., Zhao, Y., Zhao, H., Zhou, N., Zhang, Y., Chen, L., Zhou, T., Chen, G., Wu, T., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01731-x · Cited by 26
Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications
Ge, S., Zhao, Y., Liang, J., He, Z., Li, K., Zhang, G., Hua, B., Zheng, H., Guo, Q., Qi, R., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03211-w · Cited by 28
3D cell culture models in research: applications to lung cancer pharmacology
Vella, N., Fenech, A. G., & Magri, V. P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1438067 · Cited by 29
Yao, J., Li, S., Bai, L., Chen, J., Ren, C., Liu, T., Qiu, J., & Dang, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103081 · Cited by 28
Hong, S., Wang, Q. J., Cheng, Y., Luo, Y., Qu, X., Zhu, H., Ding, Z., Li, X., Wu, L., Wang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03883-5 · Cited by 26
Tian, H., Kang, Y., Song, X., Xu, Y., Chen, H., Gong, X., Zhang, W., Xu, Y., Xia, X., Gao, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.024 · Cited by 26
Juergens, R. A., Hao, D., Ellis, P. M., Tu, D., Mates, M., Kollmannsberger, C., Bradbury, P. A., Tehfe, M., Wheatley‐Price, P., Robinson, A. G., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.016 · Cited by 26
Caracciolo, D., Riillo, C., Arbitrio, M., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33038 · Cited by 29
Zhao, B., Wang, Y., Wang, Y., Chen, W., Liu, P. H., Kong, Z., Dai, C., Wang, Y., & Ma, W. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29878 · Cited by 26
The significance of Siglec-15 expression in resectable non-small cell lung cancer
HAO, J. Q., Nong, J., Zhao, D., Li, H., SU, D., Zhou, L., Dong, Y., Zhang, C., CHE, N. Y., Zhang, S. C., et al. (2020) · Neoplasma · doi:10.4149/neo_2020_200220n161 · Cited by 26
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26
Targeting glyco-immune checkpoints for cancer therapy
Manni, M., & Laubli, H. P. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1882989 · Cited by 26
Xia, L., Wang, H., Sun, M., Yang, Y., Yao, C., He, S., Duan, H., Xia, W., Sun, R., Yao, Y., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1861-5 · Cited by 29
Wong, S. K., Beckermann, K. E., Johnson, D. B., & Das, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1921140 · Cited by 28
Creemers, J. H. A., Lesterhuis, W. J., Mehra, N., Gerritsen, W. R., Figdor, C. G., de Vries, I. J. M., & Textor, J. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002032 · Cited by 26
Miyamoto, Y., Kozuki, T., Aoe, K., Wada, S., Harada, D., Yoshida, M., Sakùrai, J., Hotta, K., & Fujimoto, N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003288 · Cited by 26
Wang, L., Yang, Y., Yu, J., Zhang, S., Li, X., Wu, X., Nie, X., Liu, W., Zhang, P., Li, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14244 · Cited by 26
Kim, D. (2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.03.28 · Cited by 26
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis
Zeng, Y., Wei, X., Guo, Q., Chen, S., Sheng, D., Liu, Z., Gong, Z., & Zeng, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168244 · Cited by 27
Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
O’Leary, C. L., Pierce, N., Patel, S. P., & Naidoo, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.018 · Cited by 27
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
Liu, Z., Zhao, K., Wei, S., Liu, C., Zhou, J., Gou, Q., Wu, X., Yang, Z., Yang, Y., Peng, Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1758003 · Cited by 26
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 27
Reck, M., Barlési, F., Yang, J. C.-H., Westeel, V., Felip, E., Özgüroğlu, M., Cobo, M., Sullivan, R., Kowalski, D. M., Andric, Z. G., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1445 · Cited by 27
Self-citationReck, M., Syrigos, K., Miliauskas, S., Zöchbauer‐Müller, S., Fischer, J. R., Buchner, H., Kitzing, T. M., Kaiser, R., Radonjic, D., & Kerr, K. M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.004 · Cited by 25
Self-citationKundel, Y., Sternschuss, M., Moore, A., Perl, G., Brenner, B., & Goldvaser, H. (2020) · Cancer Medicine · doi:10.1002/cam4.3417 · Cited by 24
Zhou, J., Zhao, J., Jia, Q., Chu, Q., Zhou, F., Chu, X., Zhao, W., Ren, S., Zhou, C., & Su, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625578 · Cited by 26
Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
Principe, N., Kidman, J., Lake, R., Lesterhuis, W. J., Nowak, A. K., McDonnell, A. M., & Chee, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672747 · Cited by 25
Garon, E. B., Spira, A. I., Johnson, M. L., Bazhenova, L. A., Leach, J., Cummings, A. L., Candia, A. F., Coffman, R. L., Janatpour, M. J., Janssen, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0263 · Cited by 25
Wang, F., Zhang, Y., Hao, Y., Li, X., Qi, Y., Xin, M., Xiao, Q., & Wang, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702112 · Cited by 25
Liang, F., Zhang, C., Guo, H., Gao, S., Yang, F., Zhou, G., & Wang, G. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13256 · Cited by 25
Xu, Y., Wang, Q., Xie, J., Chen, M., Liu, H., Zhan, P., Lv, T., & Song, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.732214 · Cited by 25
Clarke, J. M., Patel, J. D., Robert, F., Kio, E. A., Thara, E., Camidge, D. R., Dunbar, M., Nuthalapati, S., Dinh, M. H., & Bach, B. A. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.004 · Cited by 25
Karayama, M., Inoue, Y., Yoshimura, K., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., Inui, N., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000396 · Cited by 25
The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
Özer, M., George, A., Goksu, S. Y., George, T. J., & Şahin, İ. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.801379 · Cited by 25
O'Byrne, K. J., Lee, K. H., Kim, S.-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J. H., Daga, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100394 · Cited by 25
Self-citationOlofsson, G. H., Mikkelsen, M. K., Ragle, A., Christiansen, A. B., Olsen, A. P., Heide-Ottosen, L., Horsted, C. B., Pedersen, C. M. S., Engell-Noerregaard, L., Lorentzen, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09349-y · Cited by 30
Zulato, E., Bianco, P. D., Nardo, G., Attili, I., Pavan, A., Bragadin, A. B., Marra, L., Pasello, G., Fassan, M., Calabrese, F., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01978-1 · Cited by 25
Blake, M. K., O’Connell, P. M., & Aldhamen, Y. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1082195 · Cited by 28
Mo, S.-F., Cai, Z.-Z., Kuai, W.-H., Li, X., & Chen, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1209243 · Cited by 31
Zou, P., Lin, R., Fang, Z., Chen, J., Guan, H., Yin, J., Chang, Z., Xing, L., Lang, J., Xue, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202302731 · Cited by 24
Mino-Kenudson, M. A., Stang, N. L., Daigneault, J. B., Nicholson, A. G., Cooper, W. A., Roden, A. C., Moreira, A. L., Thunnissen, E., Papotti, M. G., Pelosi, G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.026 · Cited by 25
Zhou, X., Wang, N., Zhang, Y., Yu, H., & Wu, Q. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01159-6 · Cited by 26
Abdelfatah, E., Long, M. D., Kajihara, R., Oba, T., Yamauchi, T., Chen, H., Sarkar, J., Attwood, K. M., Matsuzaki, J., Segal, B. H., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0383 · Cited by 26
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 25
Self-citationFelip, E., Popat, S., Dafni, U. G., Ribi, K., Pope, A., Cedrés, S., Shah, R. N., Marinis, F. D., Cove-Smith, L., Bernabé, R., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2024.12.014 · Cited by 24
Self-citationRajurkar, S. P., Mambetsariev, I., Pharaon, R. R., Leach, B., Tan, T., Kulkarni, P., & Salgia, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061870 · Cited by 25
Namikawa, K., Kiyohara, Y., Takenouchi, T., Uhara, H., Uchi, H., Yoshikawa, S., Takatsuka, S., Koga, H., Wada, N. A., Minami, H., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15514 · Cited by 24
Hu, W., Wang, G., Yarmus, L. B., & Wan, Y. (2020) · Cancers · doi:10.3390/cancers12092496 · Cited by 24
Sage, A. P., Ng, K. W., Marshall, E. A., Stewart, G. L., Minatel, B. C., Enfield, K. S. S., Martin, S. D., Brown, C. J., Abraham, N., & Lam, W. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-73787-6 · Cited by 22
Han, Y., Mu, D., Liu, T., Zhang, H., Zhang, J., Li, S., Wang, R., Du, W., Hui, Z., Zhang, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13731 · Cited by 24
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24
Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment
Tubin, S., Khan, M. K., Gupta, S., & Jeremic, B. M. (2021) · Cancers · doi:10.3390/cancers13040775 · Cited by 25
Resistance mechanisms to checkpoint inhibitors
Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 24
Sheng, L., Gao, J., Xu, Q., Zhang, X., Huang, M., Dai, X., Li, S., & Liu, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018537 · Cited by 24
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang, A., Adler, D. M., Rauterkus, G. P., Bilen, M. A., & Barata, P. C. (2021) · Cancers · doi:10.3390/cancers13205065 · Cited by 26
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Yan, Y., Cui, J., Fu, J., Su, Y.-J., Chen, X., Gu, Z., & Lin, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760737 · Cited by 24
Holtzman, L., Moskovitz, M. T., Urban, D., Nechushtan, H., Keren, S., Reinhorn, D. J., Wollner, M., Daher, S., Rottenberg, Y., Rovitzky, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.12.006 · Cited by 25
Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
Khimani, K. S., Patel, S. P., Whyte, A., & Al-Zubidi, N. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806501 · Cited by 28
Xiang, Z., Li, J., Zhang, Z., Cen, C., Chen, W., Jiang, B., Meng, Y., Wang, Y., Berglund, B., Zhai, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883655 · Cited by 23
Cuppens, K., Baas, P., Geerdens, E., Cruys, B., Froyen, G., Decoster, L., Thomeer, M., & Maes, B. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.019 · Cited by 24
Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
ter Maat, L. S., van Duin, I. A. J., Elias, S. G., van Diest, P. J., Pluim, J. P. W., Verhoeff, J. J. C., de Jong, P. A., Leiner, T., Veta, M., & Suijkerbuijk, K. P. M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.034 · Cited by 21
Clinical and technical insights of tumour mutational burden in non-small cell lung cancer
Meri-Abad, M., Moreno‐Manuel, A., Gallach, S., Fariñas, S. C., Sirera, R., Herrero, C. C., & Lewintre, E. J. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103891 · Cited by 25
Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
Dugage, M. R., Albarrán-Artahona, V., Laguna, J. C., Chaput, N., Vignot, S., Besse, B., Mezquita, L., & Auclin, É. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.029 · Cited by 24
Shen, J., Hou, H. Y., Liang, B., Guo, X., Chen, L., Yang, Y., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155104 · Cited by 24
López‐Plana, A., Fernández‐Nogueira, P., Muñoz‐Guardiola, P., Solé‐Sánchez, S., Megías‐Roda, E., Perez‐Montoyo, H., Jáuregui, P., Yeste‐Velasco, M., Gómez-Ferrería, M., Erazo, T., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32865 · Cited by 24
Chen, Y., Li, X., Liu, G., Chen, S., Xu, M., Song, L., & Wang, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01706 · Cited by 24
Advances in systemic therapy for the first-line treatment of unresectable HCC
Vogel, A., Bathon, M., & Saborowski, A. L. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1882855 · Cited by 24
Ren, S., He, J., Fang, Y., Chen, G., Ma, Z., Chen, J., Guo, R., Lin, X., Yao, Y., Wu, G., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100312 · Cited by 24
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00198-6 · Cited by 23
Zgura, A. F., Chipuc, S., Bacalbaşa, N., Hăineală, B., Maricela, A. R., & Vâlcea, S. (2025) · Cancers · doi:10.3390/cancers17030480 · Cited by 25
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 25
Chan, K. K., Tirpack, A., Vitone, G., Benson, C., Nguyen, J., Ghosh, N., Jannat‐Khah, D., Bykerk, V. P., & Bass, A. R. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11181 · Cited by 23
Impact of anatomic site on antigen-presenting cells in cancer
Zagorulya, M., Duong, E., & Spranger, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001204 · Cited by 25
Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy
Ho, A. K., Ho, A. M. ‐., Cooksley, T., Nguyen, G., Erb, J., & Mizubuti, G. B. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005029 · Cited by 24
Metadata
- Authors
- Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universidad Complutense de Madrid (ES)
- From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology–Germans Trias i Pujol Hospital, Badalona (E.C.C.) — all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2020-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2976744492
- Cited by
- 2,823
- References
- 26
- Citations by year
- 2026: 183 · 2025: 316 · 2024: 399 · 2023: 448 · 2022: 516 · 2021: 570 · 2020: 368 · 2019: 18
- FWCI
- 154.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- ipilimumab, non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, combination immunotherapy, overall survival, chemotherapy, PD-1, CTLA-4, long-term benefits, PD-L1-negative tumors, stage IV lung cancer, recurrent lung cancer, immune-related adverse events, immune-related pneumonitis
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
